



# Financial Tear Sheet

## CORPORATE PROFILE

Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.

## PRIMARY IR CONTACT


E-mail: [ir@motifbio.com](mailto:ir@motifbio.com)

## STOCK DETAILS

MTFB (ADS)	
<b>Exchange</b>	NASDAQ GS (US Dollar)
<b>Price</b>	<b>\$9.40</b>
<b>Change (%)</b>	0.00 (0.00%)
<b>Volume</b>	0
<b>52 Week Low</b>	\$5.88
<b>Market Cap</b>	\$
<b>Rolling EPS</b>	0.00
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	

Data as of March 21, 2018 9:38 a.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



# RECENT NEWS & UPCOMING EVENTS

March 20, 2018

There are currently no events scheduled.

Motif Bio Update on NDA Submission for Iclaprim

March 19, 2018

Motif Bio to present at upcoming investor and scientific conferences

February 21, 2018

Motif Bio to Present Iclaprim Data at ECCMID 2018

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
March 20, 2018	6-K/A
March 20, 2018	6-K
March 19, 2018	6-K
March 1, 2018	6-K